NAS:SRZNW (USA)
Â
Warrants (28/10/2025)
$
0.02
+0.0003 (+1.52%)
11:42 AM EST
Business Description
Surrozen Inc
NAICS : 541714
SIC : 2833
Share Class Description:
SRZNW: Warrants (28/10/2025)Description
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.44 | |||||
| Equity-to-Asset | 0.13 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.5 | |||||
| 3-Year EPS without NRI Growth Rate | -12.5 | |||||
| 3-Year FCF Growth Rate | -16.3 | |||||
| 3-Year Book Growth Rate | -3.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 42.36 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.96 | |||||
| Quick Ratio | 6.96 | |||||
| Cash Ratio | 6.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4 | |||||
| Shareholder Yield % | 5.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -152.95 | |||||
| ROA % | -108.71 | |||||
| ROIC % | -491.54 | |||||
| 3-Year ROIIC % | 154.33 | |||||
| ROC (Joel Greenblatt) % | -846.95 | |||||
| ROCE % | -87.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.28 | |||||
| EV-to-EBIT | -0.07 | |||||
| EV-to-EBITDA | -0.07 | |||||
| EV-to-FCF | -0.08 | |||||
| Earnings Yield (Greenblatt) % | -1428.57 | |||||
| FCF Yield % | -83.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SRZNW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Surrozen Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0 - 3 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surrozen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surrozen Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Surrozen Inc Frequently Asked Questions
What is Surrozen Inc(SRZNW)'s stock price today?
The current price of SRZNW is $0.02. The 52 week high of SRZNW is $3.00 and 52 week low is $0.00.
When is next earnings date of Surrozen Inc(SRZNW)?
The next earnings date of Surrozen Inc(SRZNW) is 2024-11-08 Est..
Does Surrozen Inc(SRZNW) pay dividends? If so, how much?
Surrozen Inc(SRZNW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers